Table 2.
Ablation characteristics by patient group.
| Variable | rhTSH group (n = 18) | THW group (n = 27) | P |
|---|---|---|---|
| Cumulative radioiodine activity before ablation success evaluation, GBq (mCi), mean ± SD | 5.62 ± 1.30 (152 ± 35) | 5.85 ± 1.22 (158 ± 33) | 0.34 |
|
| |||
| Ablation activity, GBq (mCi), mean ± SD | 4.70 ± 1.41 (127 ± 38) | 4.85 ± 1.11 (131 ± 29) | 0.32 |
|
| |||
| Ablation activity category, n | |||
| 3.70 GBq (100 mCi) | 9 | 11 | |
| 5.55 GBq (150 mCi) | 4 | 9 | 0.08 |
| 7.40 GBq (200 mCi) | 5 | 7 | |
|
| |||
| Patients receiving 1 additional radioiodine therapy before ablation success evaluation, % (n) | 28% (5) | 26% (7) | 0.43 |
|
| |||
| Timing of ablation success evaluation, months after ablation, mean ± SD | 10 ± 3 | 9 ± 5 | 0.18 |
|
| |||
| Ablation status, % (n) | |||
| Success | 83% (15) | 67% (18) | 0.02 |
| Failure | 17% (3) | 33% (9) | |
dxWBS: diagnostic whole-body scintigraphy; rhTSH: recombinant human thyroid-stimulating hormone; rxWBS: posttherapy whole-body scintigraphy; SD: standard deviation; Tg: serum thyroglobulin; THW: thyroid hormone withdrawal or withholding; TSH: thyrotropin.